[go: up one dir, main page]

MX2024000313A - Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2. - Google Patents

Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.

Info

Publication number
MX2024000313A
MX2024000313A MX2024000313A MX2024000313A MX2024000313A MX 2024000313 A MX2024000313 A MX 2024000313A MX 2024000313 A MX2024000313 A MX 2024000313A MX 2024000313 A MX2024000313 A MX 2024000313A MX 2024000313 A MX2024000313 A MX 2024000313A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
aryl compounds
ikzf2
modulate
compounds
Prior art date
Application number
MX2024000313A
Other languages
English (en)
Inventor
Pengyu Yang
Simon Bailey
Original Assignee
Plexium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexium Inc filed Critical Plexium Inc
Publication of MX2024000313A publication Critical patent/MX2024000313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se describen compuestos y sales de los mismos que se unen y modulan la actividad de cereblón. En algunas modalidades, la unión y modulación de cereblón da como resultado la degradación de las proteínas con dedos de zinc de la familia IKAROS (p. ej., IKZF2). Los compuestos son de fórmula I: (ver Fórmula).
MX2024000313A 2021-07-09 2022-07-08 Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2. MX2024000313A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220323P 2021-07-09 2021-07-09
US202263314992P 2022-02-28 2022-02-28
PCT/US2022/036511 WO2023283425A1 (en) 2021-07-09 2022-07-08 Aryl compounds and pharmaceutical compositions that modulate ikzf2

Publications (1)

Publication Number Publication Date
MX2024000313A true MX2024000313A (es) 2024-03-06

Family

ID=82703117

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000313A MX2024000313A (es) 2021-07-09 2022-07-08 Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.

Country Status (10)

Country Link
US (2) US11878968B2 (es)
EP (1) EP4367112A1 (es)
JP (1) JP2024529298A (es)
KR (1) KR20240035820A (es)
AU (1) AU2022306297A1 (es)
CA (1) CA3226162A1 (es)
IL (1) IL309666A (es)
MX (1) MX2024000313A (es)
TW (1) TW202317546A (es)
WO (1) WO2023283425A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2025024823A1 (en) * 2023-07-27 2025-01-30 Plexium, Inc. Salts and solid forms of compounds that modulate ikzf2

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6250751A (ja) 1985-08-29 1987-03-05 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
AU653024B2 (en) 1991-05-30 1994-09-15 Novartis Ag Substituted diaminophthalimides and analogues
RU2125980C1 (ru) 1991-11-05 1999-02-10 Смитклайн Бичам Корпорейшн Антагонисты эндотелиновых рецепторов, фармкомпозиция, способ их получения, способ подавления эндотелиновых рецепторов
AU675680B2 (en) 1992-10-14 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
IL127858A0 (en) 1996-07-01 1999-10-28 Schering Corp Muscarinic antagonists
EP0963755A3 (en) 1998-04-16 2001-03-14 Pfizer Products Inc. Use of benzopyranes for preventing allograft rejection
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
CN1156445C (zh) 1999-06-10 2004-07-07 沃尼尔·朗伯公司 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法
AU2001236605A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indole and benzimidazole inhibitors of factor xa
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
WO2002000612A1 (en) 2000-06-23 2002-01-03 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2001292350A1 (en) 2000-10-05 2002-04-15 Takeda Chemical Industries Ltd. Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
EP1345890A1 (en) 2000-11-17 2003-09-24 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2002060426A2 (en) 2001-01-03 2002-08-08 President And Fellows Of Harvard College Compounds regulating cell proliferation and differentiation
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EP1452530A4 (en) 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
WO2003074046A1 (fr) 2002-03-01 2003-09-12 Takeda Chemical Industries, Ltd. Antidepresseur
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2003216660A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
FR2841554B1 (fr) 2002-07-01 2008-01-18 Commissariat Energie Atomique Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
GB2396154B (en) 2002-10-15 2007-02-28 Merck Patent Gmbh 4,5-Dicyanoimidazole derivatives and their use in liquid crystal media and liquid crystal devices
CA2503119A1 (en) 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004063147A1 (en) 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
EP1594842A1 (en) 2003-02-22 2005-11-16 MERCK PATENT GmbH Cyanopyridone derivatives as liquid crystals
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004096210A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
ES2558761T3 (es) 2003-05-19 2016-02-08 Novartis Ag Compuestos y composiciones inmunosupresores
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
JP2005053058A (ja) 2003-08-04 2005-03-03 Fuji Photo Film Co Ltd 光情報記録媒体および情報記録方法
US20050075358A1 (en) 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
NZ548128A (en) 2003-12-29 2010-05-28 Banyu Pharma Co Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
CA2555313A1 (en) 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2005086754A2 (en) 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc. Dicationic compounds for activity against trichomonas vaginalis
US20080096935A1 (en) 2004-10-25 2008-04-24 Pinkerton Anthony B Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors
RU2398773C2 (ru) 2004-11-02 2010-09-10 Баниу Фармасьютикал Ко., Лтд. Арилоксизамещенное производное бензимидазола
US20090306052A1 (en) 2004-12-07 2009-12-10 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
US7960417B2 (en) 2005-02-24 2011-06-14 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
EP1865949B1 (en) 2005-03-11 2012-11-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20060247263A1 (en) 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7517893B2 (en) 2005-05-20 2009-04-14 The University Of North Carolina At Chapel Hill Bichalcophenes and their prodrugs as antiprotozoal agents
WO2007007910A1 (ja) 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. ヘテロ環置換ベンズイミダゾール誘導体
JP2007022937A (ja) 2005-07-13 2007-02-01 Banyu Pharmaceut Co Ltd ヘテロ環置換ベンズイミダゾール誘導体
US20080194024A1 (en) 2005-07-29 2008-08-14 Mays Robert W Culture of Non-Embryonic Cells at High Cell Density
US20080194021A1 (en) 2005-07-29 2008-08-14 Mays Robert W Use of a Gsk-3 Inhibitor to Maintain Potency of Culture Cells
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CN101490002A (zh) 2006-07-12 2009-07-22 阿斯利康(瑞典)有限公司 作为止痛剂的3-氧代异二氢吲哚-1-甲酰胺衍生物
WO2008029168A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
PT2154966E (pt) 2007-04-20 2013-11-13 Univ New York State Res Found Benzimidazóis e suas composições farmacêuticas
WO2008134618A2 (en) 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
KR20090007075A (ko) 2007-07-13 2009-01-16 제일모직주식회사 유기발광소자용 화합물 및 이를 이용한 유기전자소자
KR101585584B1 (ko) 2007-08-27 2016-01-14 키네타 포 엘엘씨 아레나바이러스 감염을 치료하기 위한 항바이러스 약물
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
KR101367514B1 (ko) 2008-07-11 2014-02-27 주식회사 엘지화학 신규한 안트라센 유도체 및 이를 이용한 유기전자소자
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
WO2011116356A2 (en) 2010-03-19 2011-09-22 Sanford-Burnham Medical Research Institute Positive allosteric modulators of group ii mglurs
EP2371828B1 (en) 2010-04-01 2018-01-10 Samsung Display Co., Ltd. Condensed-Cyclic Compound and Organic Light-Emitting Device Including the Same
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012026766A2 (ko) 2010-08-25 2012-03-01 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
WO2012031004A1 (en) 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof
ES2537190T3 (es) 2010-09-01 2015-06-03 Gilead Connecticut, Inc. Piridazinonas, procedimiento de preparación y procedimientos de utilización de las mismas
MA34553B1 (fr) 2010-10-01 2013-09-02 Bayer Ip Gmbh Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
SG189019A1 (en) 2010-10-18 2013-05-31 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
MX2013006251A (es) 2010-12-03 2013-10-01 Epizyme Inc Compuestos de purina y 7 - deazapurina substituidos como moduladores de enzimas epigeneticas.
JP5728921B2 (ja) 2010-12-10 2015-06-03 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
EP2651928A4 (en) 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
KR101284174B1 (ko) 2011-01-05 2013-07-09 한국과학기술연구원 디페닐 유도체를 포함하는 항균제
GB201103762D0 (en) 2011-03-07 2011-04-20 Vib Vzw Means and methods for the treatment of neurodegenerative disorders
CN102675194B (zh) 2011-03-16 2014-10-01 中国人民解放军军事医学科学院毒物药物研究所 含肟类的氨基衍生物、其药物组合物、其制备方法及用途
EP2691403B1 (en) 2011-03-29 2016-05-18 BIOLOG Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH New boranophosphate analogues of cyclic nucleotides
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20150105548A1 (en) 2011-05-26 2015-04-16 Abbvie Inc Anti-viral compounds
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
JP6040677B2 (ja) 2011-09-29 2016-12-07 東洋インキＳｃホールディングス株式会社 太陽電池封止材用樹脂組成物
WO2013056079A1 (en) 2011-10-13 2013-04-18 The Johns Hopkins University High affinity beta lactamase inhibitors
CN104024249A (zh) 2011-10-17 2014-09-03 埃南塔制药公司 丙型肝炎病毒抑制剂
KR101821256B1 (ko) 2011-11-03 2018-01-24 삼성디스플레이 주식회사 헤테로고리 화합물 및 이를 포함하는 유기 전계 발광 소자
EP3327017B1 (en) 2012-01-10 2019-04-24 Merck Patent GmbH Benzamide derivatives as modulators of the follicle stimulating hormone
WO2013116823A1 (en) 2012-02-02 2013-08-08 The Research Foundation Of State University Of New York Benzimidazoles and uses thereof
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
JP2015167150A (ja) 2012-05-28 2015-09-24 出光興産株式会社 有機エレクトロルミネッセンス素子
WO2013182519A1 (en) 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
WO2013191866A1 (en) 2012-06-22 2013-12-27 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
US9419231B2 (en) 2012-07-25 2016-08-16 Idemitsu Kosan Co., Ltd. Organic electroluminescence device
AU2013334874B2 (en) 2012-10-25 2018-04-05 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
KR20140111214A (ko) 2013-03-08 2014-09-18 에스에프씨 주식회사 유기발광 화합물 및 이를 포함하는 유기전계발광소자
JP2016517434A (ja) 2013-03-14 2016-06-16 エピザイム，インコーポレイティド 癌を処置するための併用療法
KR101676416B1 (ko) 2013-05-31 2016-11-15 제일모직 주식회사 유기 화합물, 유기 광전자 소자 및 표시 장치
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
JP5749870B1 (ja) 2013-07-03 2015-07-15 保土谷化学工業株式会社 有機エレクトロルミネッセンス素子
WO2015062486A1 (en) 2013-10-31 2015-05-07 Sunshine Lake Pharma Co., Ltd. Biphenyl compounds and uses thereof
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
TWI547486B (zh) 2013-12-12 2016-09-01 中央研究院 用於醣類分析及合成的化合物及方法
WO2015161016A1 (en) 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Bicyclic cgrp receptor antagonists
WO2015187850A2 (en) 2014-06-03 2015-12-10 Duke University Compounds and methods for treatment of ocular disorders
RU2753403C2 (ru) 2014-06-20 2021-08-16 Институт Пастер Корея Противоинфекционные соединения
WO2016016421A1 (en) 2014-07-31 2016-02-04 Institut Pasteur Korea 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
EP3256470B1 (en) 2014-12-23 2023-07-26 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2981797C (en) 2015-04-08 2023-11-21 Merial, Inc. Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
KR101882221B1 (ko) 2015-04-29 2018-07-26 희성소재 (주) 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
KR102002034B1 (ko) 2015-07-09 2019-07-22 에스에프씨주식회사 고효율과 장수명을 갖는 유기 발광 소자
WO2017039318A1 (en) 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP2018535190A (ja) 2015-09-16 2018-11-29 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ Ｐ５３欠損細胞の治療におけるニクロサミドの使用
WO2017051319A1 (en) 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
US11279692B2 (en) 2015-12-29 2022-03-22 Shpp Global Technologies B.V. Methods for the manufacture of an aromatic bisimide and a polyetherimide
RU2021102253A (ru) 2016-04-06 2021-03-03 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
KR102545509B1 (ko) 2016-06-02 2023-06-21 삼성디스플레이 주식회사 다환 화합물 및 이를 포함하는 유기 전계 발광 소자
WO2018010142A1 (en) 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
WO2018052945A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
EP3858837A1 (en) 2016-09-13 2021-08-04 The Regents of The University of Michigan Fused 1,4-diazepines as bet protein degraders
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2017351216C1 (en) 2016-10-24 2021-10-14 Translational Drug Development, Llc Amide compounds as kinase inhibitors
CN107973742A (zh) 2016-10-24 2018-05-01 重庆文理学院 制备3-吲哚酮类化合物的方法
US10738007B2 (en) 2016-10-24 2020-08-11 Translation Drug Development, LLC Amide compounds as kinase inhibitors, compositions and methods of treatment
CN108003089A (zh) 2016-10-27 2018-05-08 江苏三月光电科技有限公司 以蒽为核心化合物及有机电致发光器件和其应用
KR102673117B1 (ko) 2016-12-06 2024-06-07 솔루스첨단소재 주식회사 유기 화합물 및 이를 이용한 유기 전계 발광 소자
RU2019121527A (ru) 2016-12-23 2021-01-15 Эрвинэс Оперейшнс, Инк. Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
JP2020506922A (ja) 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
IT201700039562A1 (it) 2017-04-10 2018-10-10 Univ Pisa Derivati isoindolinici quali attivatori di ampk
US11339144B2 (en) 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
CN108689942B (zh) 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
EP3647311B1 (en) 2017-06-30 2023-11-01 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
WO2019032671A1 (en) 2017-08-10 2019-02-14 Coty Inc. OXIDIZING COLORED COUPLERS COMPRISING NEW AZOMETHINIC AUXOCHROMES AND COLORANTS SUBSTITUENTS AND THEIR LEUKODIFIED FORMS
JP2019034904A (ja) 2017-08-17 2019-03-07 保土谷化学工業株式会社 芳香族炭化水素基と２つのフタルイミド基を有する化合物および有機エレクトロルミネッセンス素子
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
WO2019046186A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF
US11177446B2 (en) 2017-09-14 2021-11-16 Beijing Summer Sprout Technology Co., Ltd. Silicon containing organic fluorescent materials
CN109553608B (zh) 2017-09-26 2020-12-08 北京大学 一类五元六元杂环化合物及其制备方法和治疗肿瘤的用途
CN107827809A (zh) 2017-10-31 2018-03-23 长春海谱润斯科技有限公司 一种芳胺化合物及其有机发光器件
CN111417700B (zh) 2017-12-22 2024-01-30 Dic株式会社 聚合性液晶组合物及液晶显示元件以及聚合性化合物
US20200377501A1 (en) 2018-02-20 2020-12-03 Dana-Farber Cancer Institute, Inc. Degraders of egfr and methods of use thereof
AU2019225743A1 (en) 2018-02-20 2020-07-02 Dana-Farber Cancer Institute, Inc. Degraders of EGFR and methods of use thereof
CN116332916A (zh) 2018-03-29 2023-06-27 德山新勒克斯有限公司 用于有机电气元件的化合物、使用所述化合物的有机电气元件及其电子装置
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
CN112262134B (zh) 2018-04-13 2024-05-24 阿尔维纳斯运营股份有限公司 小脑蛋白配体和包括其的双官能化合物
EP3793539A4 (en) 2018-05-15 2022-03-02 Dana-Farber Cancer Institute, Inc. COMPOUNDS FOR THE TREATMENT OF DENGUE VIRUS INFECTIONS AND OTHER INFECTIONS
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11192877B2 (en) 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3820500A4 (en) 2018-07-13 2022-04-13 Teqla Therapeutics, Inc. USE OF BCL6 INHIBITORS TO TREAT AUTOIMMUNE DISEASES
US20210226132A1 (en) 2018-07-17 2021-07-22 Hodogaya Chemical Co., Ltd. Organic electroluminescent element
AU2019309894A1 (en) 2018-07-27 2021-01-28 Biotheryx, Inc. Bifunctional compounds as CDK modulators
WO2020041405A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US11479556B1 (en) 2018-10-15 2022-10-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
EP3866927A4 (en) 2018-10-17 2022-07-27 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
CA3120530A1 (en) 2018-11-21 2020-05-28 Accutar Biotechnology Inc. Novel compounds having estrogen receptor alpha degradation activity and uses thereof
US12227488B2 (en) 2018-12-03 2025-02-18 Dana-Farber Cancer Institute, Inc. Small molecule degraders of Helios and methods of use
WO2020118036A1 (en) 2018-12-06 2020-06-11 The Children's Medical Center Corporation Antibacterial compounds and uses thereof
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
KR102720178B1 (ko) 2019-01-02 2024-10-21 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
KR20210112336A (ko) 2019-01-04 2021-09-14 지앙수 헨그루이 메디슨 컴퍼니 리미티드 6-옥소-1,6-디하이드로피리다진 유도체, 이의 제조 방법, 및 이의 의약적 용도
US20220105188A1 (en) 2019-02-07 2022-04-07 Korea Research Institute Of Chemical Technology Target protein eed degradation-inducing degraducer, preparation method thereof, and pharmaceutical composition for preventing or treating diseases related to eed, ezh2, or prc2, comprising same as active ingredient
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
EP3931186A1 (en) 2019-02-25 2022-01-05 CHDI Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
WO2020198435A1 (en) 2019-03-26 2020-10-01 The Regents Of The University Of Michigan Small molecule degraders of stat3
CN110092804A (zh) 2019-03-29 2019-08-06 广州盈升生物科技有限公司 一种含双环基团的嘌呤化合物及其制备方法
EP3966870B1 (en) 2019-05-09 2024-04-03 Merck Patent GmbH Aromatic compounds
JP2022532178A (ja) 2019-05-10 2022-07-13 上海海雁医薬科技有限公司 置換フェニルプロペニルピリジン誘導体、その調製方法及びその医学的使用
CN112010858B (zh) 2019-05-31 2023-07-18 四川海思科制药有限公司 一种btk抑制剂及其制备方法和药学上的应用
CN112047932B (zh) 2019-06-05 2022-11-08 中国药科大学 吡唑类脾酪氨酸激酶抑制剂及其制备方法与用途
CA3143163A1 (en) 2019-06-10 2020-12-17 Washington University Swell1-lrrc8 complex modulators
CN112513029B (zh) 2019-06-21 2023-10-24 上海翰森生物医药科技有限公司 含氮芳基磷氧化物类衍生物、其制备方法和应用
CN112125885A (zh) 2019-06-25 2020-12-25 中国药科大学 苯并吲哚类双功能分子衍生物及其制备方法与应用
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN114401719A (zh) 2019-07-23 2022-04-26 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶7的抑制剂及其用途
US20230002371A1 (en) 2019-09-13 2023-01-05 Biotheryx, Inc. Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20220380368A1 (en) 2019-09-19 2022-12-01 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
CN112552293A (zh) 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021078227A1 (zh) 2019-10-25 2021-04-29 江苏恒瑞医药股份有限公司 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
CN118955495A (zh) 2019-11-15 2024-11-15 柳韩洋行 具有2,3-二氢-1h-茚或2,3-二氢苯并呋喃部分的衍生物或其药学上可接受盐及含其的药物组合物
AR120481A1 (es) 2019-11-19 2022-02-16 Bristol Myers Squibb Co Compuestos útiles como inhibidores de la proteína helios
CN110885332B (zh) 2019-12-06 2022-03-18 中国人民解放军第二军医大学 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
CA3162261A1 (en) 2019-12-17 2021-06-24 Nikolai Kley Compounds modulating protein recruitment and/or degradation
EP4076530A4 (en) 2019-12-17 2024-04-10 Orionis Biosciences, Inc. BIFUNCTIONAL AGENTS FOR RECRUITMENT AND/OR DEGRADATION OF PROTEINS
MX2022007885A (es) 2019-12-23 2022-09-19 Shanghai Jemincare Pharmaceuticals Co Ltd Metodo y aplicacion de preparacion de compuesto como agente de degradacion de proteinas.
AU2021205974A1 (en) 2020-01-09 2022-07-21 Senseion Therapeutics, Inc. Suppression of inflammasome activation
WO2021170078A1 (zh) 2020-02-28 2021-09-02 上海润石医药科技有限公司 一种csf-1r激酶抑制剂的用途
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
WO2021194319A1 (en) 2020-03-27 2021-09-30 Uppthera Vanillin derivative compounds inducing selective degradation of plk1
CN113509557A (zh) 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
WO2021236885A1 (en) 2020-05-21 2021-11-25 Dana-Farber Cancer Institute, Inc. Piperidine-2,6-diones as small molecule degraders of helios and methods of use
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4228651A4 (en) 2020-10-16 2024-11-27 Dana-Farber Cancer Institute, Inc. HELIOS SMALL PIPERIDINYL MOLECULE DEGRADERS AND METHODS OF USE
CN112430216B (zh) 2020-11-23 2022-12-09 六夫丁作物保护有限公司 消杀剂和农药中苯并咪唑类化合物的制备方法
CN113013346B (zh) 2021-02-25 2023-06-27 上海弗屈尔光电科技有限公司 三元组合物和含有该组合物的有机电致发光元件及应用

Also Published As

Publication number Publication date
IL309666A (en) 2024-02-01
AU2022306297A1 (en) 2024-02-08
US11878968B2 (en) 2024-01-23
US20230265071A1 (en) 2023-08-24
JP2024529298A (ja) 2024-08-06
CA3226162A1 (en) 2023-01-12
KR20240035820A (ko) 2024-03-18
US20240246935A1 (en) 2024-07-25
WO2023283425A1 (en) 2023-01-12
EP4367112A1 (en) 2024-05-15
TW202317546A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
MX2024000313A (es) Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.
EA202191730A1 (ru) Ингибиторы kif18a
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
MX2021005350A (es) Compuestos de piridazinona y usos de los mismos.
EA201490407A1 (ru) Содержащие гидразид модуляторы нуклеарного транспорта и их применения
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
BR112023021978A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
UA113712C2 (xx) Антитіло до fap і способи його застосування
JOP20180104A1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
EA200970729A1 (ru) Варианты, происходящие из actriib, и их применение
EA201101478A1 (ru) Композиции и способы модулирования связывания ретинола с ретинолсвязывающим белком 4 (rbp4)
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
EA201491264A1 (ru) Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
ATE459653T1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
NZ626945A (en) Chimeric factor viii polypeptides and uses thereof
TN2009000182A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
EA201001315A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ СТЕАРОИЛ-CoA-ДЕСАТУРАЗЫ
MX340870B (es) Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
WO2011080494A3 (fr) Composition cosmétique, procédé de traitement cosmétique, kit et composé
MX2014014708A (es) Nuevos compuestos biciclicos de tiofenilamida.
MX2020007152A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
WO2008143876A3 (en) Agents and assays for modulating neurodegeneration